Cure My Disease

Don't miss your cure!

 Log in / Sign up

Minimally invasive eye surgery could ease a rare form of glaucoma

NCT ID NCT07713056

Disease control Sponsor: Zhongnan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study looks at pigmentary glaucoma, a rare type of glaucoma caused by pigment flakes blocking fluid drainage in the eye. Researchers are testing a minimally invasive surgery called ab-interno 120° trabeculotomy, which makes a small cut in the eye's drainage tissue to help fluid flow out and lower pressure. The study follows 11 people for 6 months after surgery to see if eye pressure drops and if they need fewer glaucoma medications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a minimally invasive glaucoma surgery called ab-interno 120° trabeculotomy
What this could lead to
If successful, this surgery could offer a safer, effective way to lower eye pressure and reduce medication use in people with pigmentary glaucoma.
What could go wrong
This is a small, early study with only 11 participants and no comparison group, so results may not apply to all patients. The surgery may not lower pressure enough or could have complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 11 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study included patients with pigmentary glaucoma who underwent primary isolated ab-interno 120° trabeculotomy at Zhongnan Hospital of Wuhan University. All patients had complete baseline data (including intraocular pressure, visual field, and OCT retinal nerve fiber layer measurements) and at least 6 months of follow-up data. Patients with other types of glaucoma, prior ocular trauma or surgery history, combined intraoperative procedures, severe systemic diseases, or incomplete key data were excluded.

Ages

16 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Meet the clinical diagnostic criteria for pigmentary glaucoma, with typical signs of pigment dispersion syndrome, extensive trabecular meshwork pigmentation, pathological intraocular pressure elevation, glaucomatous optic nerve damage, and characteristic visual field defects; * Underwent primary isolated ab-interno 120° trabeculotomy as the initial surgical treatment; * Have complete preoperative and postoperative examination data, including slit-lamp biomicroscopy, gonioscopy, intraocular pressure, visual field, and OCT RNFL measurements; * Able to complete regular follow-up for at least 6 months postoperatively. Exclusion Criteria: * Patients with exfoliation syndrome, exfoliative glaucoma, or other types of primary or secondary glaucoma; * Patients with a history of ocular trauma, intraocular surgery, uveitis, severe retinopathy, or other ocular diseases affecting intraocular pressure and visual function assessment; * Patients who underwent combined procedures such as concurrent cataract surgery or other anti-glaucoma surgeries during the operation; * Patients with severe systemic diseases, cognitive or psychiatric disorders that prevent cooperation with examinations and follow-up; * Patients with missing key clinical or follow-up data that preclude efficacy and prognosis evaluation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pigmentary glaucoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pigmentary glaucoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Zhongnan Hospital of Wuhan University

    RECRUITING

    Wuhan, Hubei, 430071, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.